

REVIEW ARTICLE

The involvement of microglia in Alzheimer's disease: a new dog in the fight

Correspondence Juliet M. Taylor and Peter J. Crack, Department of Pharmacology and Therapeutics, University of Melbourne, 8th Floor, Medical Building, Grattan St, Parkville, Melbourne 3010, VIC, Australia. E-mail: juliett@unimelb.edu.au; pcrack@unimelb.edu.au

Received 4 September 2018; **Revised** 17 October 2018; **Accepted** 29 October 2018

Zachery Moore, Juliet M Taylor and Peter J Crack 

Neuropharmacology Laboratory, Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, VIC Australia

First described clinically in 1906, Alzheimer's disease (AD) is the most common neurodegenerative disease and form of dementia worldwide. Despite its prevalence, only five therapies are currently approved for AD, all dealing with the symptoms rather than the underlying causes of the disease. A multitude of experimental evidence has suggested that the once thought inconsequential process of neuroinflammation does, in fact, contribute to the AD pathogenesis. One such CNS cell type critical to this process are microglia. Plastic in nature with varied roles, microglia are emerging as key contributors to AD pathology. This review will focus on the role of microglia in the neuroinflammatory response in AD, highlighting recent studies implicating aberrant changes in microglial function in disease progression. Of critical note is that with these advances, a reconceptualization of the framework in which we view microglia is required.

LINKED ARTICLES

This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit <http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc>

Abbreviations

5XFAD, 5X familial Alzheimer's disease mutation; AAV, adeno-associated virus; ABI3, ABI gene family member 3; ACH, amyloid cascade hypothesis; AD, Alzheimer's disease; APOE, apolipoprotein E; APP, amyloid precursor protein; APP_{SWE}/PS1_{ΔE9}, APP containing Swedish mutation and PS1 containing δ E9 mutation; CD, cluster of differentiation; CK-p25, cyclin-dependant kinase 5 protein 25; CLU, clusterin; CR1, complement receptor 1; DAM, damage-associated microglia; DAMP, damage-associated molecular pattern; GWAS, genome-wide association study; IBA1, ionized calcium-binding adapter molecule 1; IL1RAP, IL-1 receptor accessory protein; iPSC, induced pluripotent stem cell; IRF, IFN regulatory factor; LOAD, late onset Alzheimer's disease; MCI, mild cognitive impairment; MV, microvesicle; PS1, presenilin 1; RIPK1, receptor-interacting serine/threonine-protein kinase 1; SP, senile plaque; TLR, Toll-like receptor; TREM2, triggering receptor expressed on myeloid cells 2

Alzheimer's disease

Pathologically, Alzheimer's disease (AD) is characterized by the death of pyramidal neurons and synapses in the cerebral cortex and certain subcortical regions, with classical hallmarks of senile plaque (SP) deposits and hyperphosphorylation of the microtubule-associated protein tau. In particular, this loss occurs in the hippocampus resulting in gross atrophy of the brain and increased ventricular spaces. This presents clinically as a progressive pattern of worsening cognition and behavioural function. This pattern is divided into three stages: preclinical, mild cognitive impairment (MCI) and dementia (Jack *et al.*, 2011). Despite identification of genetic mutations that confer significant risk factors for disease, the underlying cause of AD remains unproven and as such raises difficulties in definitive diagnoses. Indeed, the MCI stage of AD, considered a prodromal stage of disease, is often attributed to normal ageing (Dubois and Albert, 2004).

The amyloid cascade hypothesis (ACH) was developed following the identification that SPs are composed of **amyloid beta** (A β) and that these deposits are unique to AD. The ACH posits that A β accumulation is a critical event in AD pathology. First articulated in 1992 by Hardy and Higgins (1992), the ACH originally postulated that A β accumulation is causative of AD pathology, although this has now evolved to contend that A β accumulation is a central event in AD pathology (Pimplikar, 2009). Regardless of the validity of the ACH, it has driven AD research and aided in our understanding of underlying biological mechanisms.

However, this has not translated into clinical trial results. All A β -directed therapies have failed in clinical trials, many in multiple attempts (Cummings *et al.*, 2014). Similarly, the vast majority of non-A β -directed therapies have also failed. This results in AD having one of the highest failure rates of any disease at 99.5–99.6% (Cummings *et al.*, 2014; Calcoen *et al.*, 2015). Pfizer has even gone as far to abandon the field entirely, citing money can be better spent elsewhere (Hawkes, 2018). This has not been unnoticed by those outside of the scientific sphere with individuals becoming disconcerted with the scientific process (Cummings *et al.*, 2014; Mannix, 2018).

To address this, it is clear that a re-evaluation of the precise role of the various pathologies seen in AD is required; one that accounts for the complex milieu observed. In concordance, our therapeutic approaches should also follow a re-evaluation. Once such reevaluation involves investigating the role of neuroinflammation within AD.

Neuroinflammation

The term 'neuroinflammation' refers to immune-related responses, in particular, the innate immune response that occurs within the CNS. Neuroinflammation is normally seen throughout the CNS with roles in both cellular and tissue homeostasis as well as proper neuronal functioning (Xanthos and Sandkuhler, 2014). Under normal physiological conditions, this response is self-limiting. This acute form of neuroinflammation contrasts with the chronic form observed in

AD that sees a failure of the immune clearance mechanism (Maderna and Godson, 2003; Shastri *et al.*, 2013).

Neuroinflammation is a complex process that involves a number of cell–cell interactions within the CNS (Skaper *et al.*, 2018). The inflammatory cascade is principally initiated through two glial cell types: microglia and astrocytes (Perry *et al.*, 2010). Upon recognition of an initial stimulus, these cells secrete a number of hallmark pro-inflammatory cytokines including **TNF α** , **IL-1 β** and **IL-6**, as well as a number of chemokines that recruit further glial cells. These pro-inflammatory mediators can then facilitate the neurodegeneration of otherwise healthy neighbouring neuronal populations, with the cellular contents and damage-associated molecular patterns (DAMPs) produced and secreted by these dying neurons further contributing to the inflammatory milieu.

Neuroinflammation in AD is considered to be a chronic and detrimental process (Eikelenboom *et al.*, 2006). Human *post mortem* examination of AD individuals consistently reports enhanced levels of microgliosis and astrogliosis surrounding A β plaques (Heneka *et al.*, 2014). This is in concordance with increased levels of inflammatory cytokines and chemokines (Heneka *et al.*, 2014). Furthermore, levels of neuroinflammation have been shown to correlate with disease progression and impairments in cognition (Morris *et al.*, 2014; Heneka *et al.*, 2014). Recent studies suggest that microglia are the critical cell type that contributes to this neuroinflammatory-related pathology (Sarlus and Heneka, 2017).

Microglia

Microglia are a class of innate immune cells within the CNS. Unlike other CNS glial cell types, they share a myeloid lineage with their peripheral counterparts macrophages (Ginhoux *et al.*, 2013). Critically, microglia are formed from primitive macrophage progenitors that infiltrate the brain during development (Ginhoux *et al.*, 2010). These microglia have a defined core gene set that distinguishes them from related peripheral cells (Butovsky and Weiner, 2018). The median lifespan for a single microglial cell is 15 months, over half the lifetime of a mouse (Fuger *et al.*, 2017). However, when genetically depleted, microglia can repopulate to normal cell levels within 5 days (Bruttger *et al.*, 2015). Under homeostatic conditions, microglial repopulation is shown to be exclusively from CNS residing progenitor cells (Butovsky and Weiner, 2018). However, it is now appreciated that under certain conditions, infiltration of peripheral myeloid cells can indeed differentiate into microglia (Cronk *et al.*, 2018; Lund *et al.*, 2018). These cells do express a subset of the unique microglial gene signature but have differential functional roles (Butovsky and Weiner, 2018). Microglial proliferation is increased in a number of neurodegenerative conditions in mice, including AD (Gomez-Nicola *et al.*, 2013).

Microglia exhibit a number of cell surface markers allowing for their identification and distinction from other immune cell types. Both microglia and peripheral macrophages are macrophage-1 antigen and **cluster of differentiation** 11b (CD11b) positive, whereas they can be distinguished based on being CD45^{low} and CD45^{high}

respectively (D'Mello *et al.*, 2009). Ionized calcium-binding adapter molecule 1 (IBA1) is also used as a microglial marker and has historically been used as a marker for microglial 'activation' (Ito *et al.*, 1998). IBA1 has been shown to be involved in actin remodelling and subsequently phagocytosis, a key functional role that microglia are involved in (Ohsawa *et al.*, 2004). CD68 expression has also been used with IBA1 to identify 'phagocytic' microglia (Boche *et al.*, 2013).

Microglia fulfil a number of varied roles within the CNS including the immune response, maintenance of homeostasis, extracellular signalling, phagocytosis, antigen presentation and synaptic pruning (Kettenmann *et al.*, 2011; Walker *et al.*, 2014). The varied roles of microglia may be attributed to their limited self-renewal under normal physiological conditions (Lawson *et al.*, 1992).

It follows that microglial populations are heterogeneous in nature; populations isolated from different regions within the brain under different conditions will ultimately differ in phenotype, associated markers and function (Wes *et al.*, 2016). In an effort to characterize microglia, the M1/M2 dichotomy was adopted from their peripheral macrophage counterparts, representing 'classical' and 'alternative' activation states. Whilst popular for some time, this is now considered an oversimplification of the vast array of phenotypes microglia can adopt. Ransohoff (2016) provides the most compelling argument for this. Briefly, these microglial subtypes are based on specific cytokines that induce each phenotype as described *in vitro*, which fails to account for the complex milieu seen in the CNS. Furthermore, the suggested spectrum view of microglia with 'M1 like' and 'M2 like' phenotypes as bookends also fails, with differing disease states failing to identify an axis on which polarization occurs. This is further compounded with the original notion of M1/M2 macrophages also under debate (Martinez and Gordon, 2014). Extending this, describing microglia as either 'activated' or 'resting/quiescent' further hinders our understanding of these cells and conclusions we subsequently draw. A more appropriate view of microglia (Figure 1) shifts away from such pigeonholing and rather views them as an extensive array of distinct, though overlapping phenotypes with corresponding functions. This is not to entirely dismiss previous research. Rather, a more holistic view is required when drawing inferences about microglial phenotype and subsequent function.

Microglia transcriptomic changes in AD

A number of efforts have been made to accurately characterize microglia primarily through transcriptomic approaches. Although the first microglial-specific characterization is less than 5 years old, this approach has now expanded and aided in understanding the complexity that is microglial phenotype (Orre *et al.*, 2014). By utilizing direct RNA sequencing (RNAseq), the microglial 'sensome' has been identified as a distinct group of transcripts encoding for ligand sensing proteins that changes in ageing (Hickman *et al.*, 2013). In the cyclin-dependant kinase 5 protein 25 (CK-p25) inducible mouse model of neurodegeneration, which shows similar transcript profiles to the 5X familial Alzheimer's disease mutation (5XFAD) AD model, Mathys *et al.* (2017) utilized a




Figure 1

A proposed new framework for microglia characterization. The M1/M2 paradigm for microglial characterization is now recognized as a vast oversimplification of microglial phenotypes and functions. Rather than pigeonholing these cells as either 'good' or 'bad', a context-dependant label, a more appropriate view is to recognize them as a distinct array of overlapping phenotypes. Microglia can in fact have altered expression levels of both classical M1 and M2 markers. This framework also includes shifting away from notions of resting/quiescent and active microglia. Whilst this may seem an issue of semantics, not only does it not dismiss these phenotypes entirely as previously done in the past, it also allows for a more holistic view when interpreting data. For simplicity, morphological differences have not been illustrated. Created with BioRender.

single-cell RNAseq to characterize microglial heterogeneity (Hargis and Blalock, 2017). Clustering of transcription profiles revealed a number of disease-specific microglial states that were not observed in wild-type controls. In a separate study in the 5XFAD AD model, a single-cell RNAseq was used to profile all immune cell types within the brain, after which a cluster of microglial cells termed the damage-associated microglia (DAM) was identified. These cells were associated with plaque, involved the down-regulation of inhibitory checkpoints and were conserved in humans (Keren-Shaul *et al.*, 2017). Evidence has shown that both triggering receptor expressed on myeloid cells 2 (TREM2) and apolipoprotein E (APOE), known AD risk factors, act as regulators for the phenotypic switching of microglia (Krasemann *et al.*, 2017). Utilizing the double transgenic AD mouse model containing amyloid precursor protein (APP) with the Swedish mutation and **presenilin (PS) 1** with the delta E9 mutation (APP_{SWE}/PS1_{ΔE9}), in parallel to models of multiple sclerosis and amyotrophic lateral sclerosis, mRNA counts using Nanostring technology identified a molecular signature of DAM dependant on both TREM2 and APOE signalling.

Ageing alone is known to alter microglial phenotype deleteriously, yet its exact contribution to disease remains unknown (Olah *et al.*, 2018; Silvin and Ginhoux, 2018). This includes observations of microglial priming, in where aged microglial populations exhibit an increased pro-inflammatory response upon insult (Norden and Godbout, 2013; Rawji *et al.*, 2016). In aged mice, peripheral injections of **LPS** resulted in increased levels of pro-inflammatory cytokine levels when compared to young mice (Godbout *et al.*, 2005; Henry *et al.*, 2009). In addition, *ex vivo* microglia isolated from adult mice show greater secretion of both IL-6

and TNF α (Njie *et al.*, 2012). Gene ontology analysis on transcriptomic data from young and aged mice reveals that these changes are largely **IFN**-dependant (Deczkowska *et al.*, 2017). These changes are accompanied by morphological alterations, most notably with observations of hypertrophy (Conde and Streit, 2006). In addition to altered immune-related functions, phagocytotic functions are also altered, with the ability to phagocytose A β_{1-42} decreasing with age (Floden and Combs, 2011). However, whether this is indeed *bona fide* senescence has not been determined (Baker and Petersen, 2018). Furthermore, issues arise when attempts are made to distinguish the individual contributions that either AD or normal ageing makes on observed dysfunction.

The extent that these findings translate to humans is unclear. Whilst whole brain transcriptional profiles for humans and rodents in ageing alone are concordant, when AD humans and AD mouse models are examined concordance is not observed (Hargis and Blalock, 2017). Different rodent models of AD reproduce different features and states of disease. Critically, all are based on familial disease states. Additionally, whilst similar profiles are seen within matched AD individuals, separate rodent models result in separate transcriptomic profiles (Hargis and Blalock, 2017). Furthermore, examination of whole tissue or entire cell populations has the potential to mask distinct populations. In an AD model containing APP_{SWE} and the N141I mutation in PS2, genes that were altered in whole brain tissue were found to be highly enriched in microglia and astrocytes; however, only a fraction of these genes was in fact up-regulated when examined in these cell types as a specific population. Of these, microglia accounted for 87% (Kim *et al.*, 2016). Single-cell RNAseq continually reports multiple glial cell populations, even in wild-type mice (Zeisel *et al.*, 2015). However, the extent that individual microglial populations translate across both models and species is yet to be fully explored. Epigenomic signals do however appear to be conserved between mice and humans. In the CK-p25 AD-like model, conserved transcriptional changes were shown to be associated with immune-related genes, as well as conserved chromatin dynamics (Gjoneska *et al.*, 2015).

One such technique to overcome this is the use of induced pluripotent stem cells (iPSCs) from humans. Although a recent technique, these cells are indeed microglial-like and have been validated as a viable research tool (Abud *et al.*, 2017; Pocock and Piers, 2018). The generation of microglial-like iPSCs from APOE4 carriers shows transcriptomic changes alongside impaired phagocytosis of A β (Lin *et al.*, 2018). Microglial iPSCs have recently been used to investigate specific missense mutations in TREM2, a newly identified AD risk factor (Garcia-Reitboeck *et al.*, 2018).

Microglia morphology changes in AD

A key constituent of the plastic nature of microglia is their capacity for rapid morphological transformations. It has been widely observed that under normal physiological conditions, 'quiescent' microglia adopt a ramified morphology, and 'activated' microglia appear ameboid in shape (Boche *et al.*, 2013). Furthermore, this transition is stepwise in nature. Multiple morphological measurements available can be used to

compare separate microglia. Under normal conditions, microglia exhibit an altered morphology that is region-dependant (Lawson *et al.*, 1990). Microglia from LPS-treated mice were shown to differ in measurements of cell perimeter, roundness and soma size (Kongsui *et al.*, 2015). In the dual Indiana and Swedish APP mutation AD model, plaque-associated microglia show alterations in branch length, area and ramification when compared to wild-type controls (Plescher *et al.*, 2018). Examination of human AD autopsy samples also reveals distinct morphological microglial populations. In a human cohort, five distinct morphological types were identified in AD and cognitively normal controls. Differences were seen in various regions of the hippocampus (Bachstetter *et al.*, 2015). However, further work is required to elucidate the link between morphology and phenotype. Microglia that exhibit similar morphologies can indeed differ in underlying phenotype (Wes *et al.*, 2016). Although a recent technique, these studies provide evidence for novel inferential analysis of microglial function through morphology.

Microglial function in AD

Functional alterations in microglia are indeed observed contiguous to phenotypic changes, although the translational effect of these changes varies (Figure 2). The initial sensing of the neuroinflammatory trigger by the A β peptide and its aggregates *via* microglia is varied. This sensing occurs through a number of receptors, including **Toll-like receptors** (TLRs), **NOD-like receptors**, receptors for advanced glycation endproducts, formyl peptide receptors, scavenger receptors, pentraxins and the complement cascade. All of which are involved in the initiation of a neuroinflammatory response through a number of signalling pathways (Salminen *et al.*, 2009). This sensing can also occur through the NOD, leucine-rich-containing family, pyrin domain-containing-3 inflammasome, multiprotein complexes involved in the maturation and secretion of pro-inflammatory cytokines IL-1 β and IL-18 (Halle *et al.*, 2008). The most studied of the receptors involved in this sensing are the TLRs. TLRs belong to a superfamily of pattern recognition




Figure 2

Alterations in microglial phenotype and function as seen in AD. A multitude of experimental evidence has now demonstrated that these changes are indeed deleterious and may in fact contribute to disease progression. Created with BioRender.

receptors recognizing both DAMPs and pathogen-associated molecular patterns. Of these, the **TLR2** and **TLR4** subtypes are considered critical in A β recognition. Microglial TLR2 recognition of A β is considered the principal method that triggers the neuroinflammatory response (Liu *et al.*, 2012). Downstream TLR signalling through NF κ B, activator protein 1 and IFN regulatory factor (IRF) pathways lead to pro-inflammatory gene transcription (Miyake, 2007).

Microglia are also involved in the clearance of A β through endocytosis. This process is dependent on whether A β is in a fibrillar or soluble oligomeric state, resulting in phagocytic or macropinocytotic processes respectively. Fibrillar A β is recognized through an assembly of receptors to form a cell surface receptor complex, consisting of class A scavenger receptor, class B scavenger receptor, α 6 β 1 integrin, CD14, CD36, CD47, TLR2, TLR4, TLR6 and TLR9 (Bamberger *et al.*, 2003; Lee and Landreth, 2010). Of these receptors, the TLRs appear to be the most crucial, with TLR activation increasing fibrillar A β clearance through phagocytosis (Tahara *et al.*, 2006). Furthermore, TLR2 and TLR4 ablation results in a failure of the cell surface receptor complex to recognize A β and subsequently initiate phagocytosis (Reed-Geaghan *et al.*, 2009). Soluble A β species are cleared by microglia through a process known as fluid phase macropinocytosis. Soluble A β is brought into the cell through an invagination of the cellular membrane, which then closes to form a vesicle. This uptake also occurs in astrocytes, although not as effectively (Mandrekar *et al.*, 2009). Excessive A β deposits and neurofibrillary tangles have been shown to impair the A β -related clearance abilities of the recruited microglia and astrocytes, compounding the issue (Yamanaka *et al.*, 2012).

Microglia also perform various functions through the release of extracellular microvesicles (MVs) through exocytosis. MVs have been shown to be potent modulators of inflammation and immunity, and when released, MVs can stimulate synaptic activity both *in vitro* and *in vivo* (Sadallah *et al.*, 2011; Antonucci *et al.*, 2012). Critically, MVs, likely of microglial origin, are elevated within AD individuals. Examination of these MVs showed that they present toxicity towards neurons and promote the formation of A β (Joshi *et al.*, 2014).

Microglia activity within AD can also affect tau and drive tau-related pathology (Maphis *et al.*, 2015). Analysis of human brain samples has demonstrated a senescent morphological microglial phenotype that is associated with tau (Streit *et al.*, 2009). In addition, microglial-mediated inflammation has been linked to the aggregation and phosphorylation of tau. In wild-type mice, LPS-induced inflammation has been shown to induce tau aggregation with this further enhanced in transgenic mice lacking the microglial fractalkine receptor **CX₃CR1**. (Bhaskar *et al.*, 2010).

It is known that microglia are involved in synaptic pruning, a process critical not only during development but also in the mature brain (Paolicelli *et al.*, 2011; Hong *et al.*, 2016). Initially thought to engulf whole synapses, recent evidence questions this with the process of 'trogocytosis' observed, where partial phagocytosis has been linked to selective pruning (Weinhard *et al.*, 2018). Aberrant engulfment of synapses by microglia can lead to dysfunction. In lupus, a microglial-mediated synapse loss has been observed, which was rescued upon promoting an anti-inflammatory

phenotype (Bialas *et al.*, 2017). This is now being investigated within AD, where it is suggested that microglia may indeed be involved in such a process (Hong *et al.*, 2016). The genome-wide association study (GWAS) has identified a risk gene, clusterin (CLU), which encodes for the receptor complement component 3b, and has been shown to be critical in the maturation of developing neural circuits by microglia (Schafer *et al.*, 2012).

Similarly, it has recently been observed that microglia can execute neuronal death through phagocytosis on stressed but otherwise viable neurons, a process termed phagoptosis (Brown and Neher, 2014). This is due to an increase in various 'eat me' signals (phosphatidylserine, complement component 1q, calreticulin, de-sialylated glycoprotein) and/or loss of 'don't eat me' signals (glycoprotein, CD47, neuraminidase) presented on neuronal surfaces. In an inflammatory setting, both microglia and astrocytes release milk fat globule EGF8 that is able to bind to exposed phosphatidylserine, opsonising the neuron. In excessive neuroinflammation, this process is skewed where microglia are able to phagocytose healthy neurons (Brown and Neher, 2012). In neuronal-glial co-cultures stimulated with either LPS or A β , a lack of discrimination occurs between stressed and healthy neurons targeted for phagoptosis by microglia (Neniskyte *et al.*, 2011).

GWAS microglia

Genetic mutations in either APP or PS1/2 remain the only identified causative agents of early onset AD, with genetic determinants for late onset AD (LOAD) less characterized. Recent GWASs have revealed a number of genetic mutations that confer an increased risk of LOAD. Interestingly, a number of these SNPs reside in genes that directly relate to innate inflammatory function. As such, collections of these variants have the potential to drive pathological neuroinflammation and contribute to the progression and exacerbation of LOAD. These genes include APOE, major histocompatibility complex class II, complement receptor 1 (CR1), CLU, membrane spanning 4 domain subfamily A and ATP-binding cassette sub-family A member 7 (ABCA7) (Villegas-Llerena *et al.*, 2016). Of the set of inflammatory-related genes identified by GWAS, a subset has also been shown to play additional roles in microglial function. The genes **CD33** (Siglec-3), TREM2, CR1, **PLC γ 2** (*PLCG2*), ABI gene family member 3 (*ABI3*) and **IL-1 receptor accessory protein** (*IL1RAP*) have been shown to be involved in the regulation of phenotypic switching and A β phagocytosis (Ramanan *et al.*, 2015). Of these, the contributions of CD33 and TREM2 to AD pathology have been explored in a rodent model.

CD33 is a type-I transmembrane receptor and member of the sialic acid-binding immunoglobulin-type lectins (Siglec) family and is expressed exclusively on immune cells. CD33 has been shown to mediate cell-cell interactions that inhibit or restrict immune responses, although no precise role for CD33 has been demonstrated in the CNS (Crocker *et al.*, 2012). Carriers of CD33 SNPs have been shown to have higher A β deposits, as measured through A β deposits in both cortical and hippocampal regions, in addition to decreased soluble A β 1–42 levels. Furthermore, primary microglia isolated from these knockout mice showed an increased ability

to phagocytose A β _{1–42}, whilst CD33 overexpression in the BV-2 murine microglial cell line inhibited phagocytosis (Griciuc *et al.*, 2013). Functioning as a type-I transmembrane glycoprotein, TREM2 is predominantly expressed on CNS-residing microglia. *Post mortem* examination of AD-affected individuals reported increased levels of TREM2 within microglia surrounding A β plaques (Lue *et al.*, 2015). The rs75932628 SNP identified by GWAS leads to a loss of function mutation, with APP_{SWE}/PS1_{ΔE9} mice overexpressing this mutation demonstrating increased hippocampal A β deposits (Ulrich *et al.*, 2014). These mice also exhibited impaired recruitment of microglia to A β plaques. Knockout of TREM2 in both APP_{SWE}/PS1_{ΔE9} and 5xFAD mice leads to increased A β deposits and attenuated microglial activity. It was concluded that this effect was due to the infiltration of peripheral macrophages lacking TREM2 enhancing the pathology (Wang *et al.*, 2015). However, a second study investigating TREM2 knockout in 5xFAD mice found that reduced TREM2 expression conferred an increased A β load despite a similarly observed attenuated microglial function (Jay *et al.*, 2015). Within the same 5xFAD mice, a recent study has demonstrated that gene dosage increases of TREM2 alters microglia morphology and function. Critically, increases were seen in phagocytosis-related genes and alterations in plaque types (Lee *et al.*, 2018). The contrasting nature of these two studies is thought to be attributable to the differences in A β accumulation rates between mouse models (Leavy, 2015). Despite this, both studies show a crucial role for TREM2 in the production of the pro-inflammatory cytokines TNF α and IL-1 β .

APOE4 is the most common gene identified by the GWASs undertaken, with this allele conferring the major genetic risk for LOAD. Forty two families with a family history of LOAD were analysed for the E4 allele variant and individuals homozygous for this allele succumbed to LOAD in over 90% of the cases examined (Corder *et al.*, 1993). This gene dosage effect of APOE4 has been replicated in a number of subsequent studies. Indeed, a key comparison was made in a GWAS and the SNPs of the APO allelic variant individuals possess were identified. Utilizing CRISPR/Cas9 editing, Lin *et al.* (2018) recently generated isogenic iPSC lines containing either APOE3 or APOE4, which were then differentiated to microglial-like cells. APOE4-containing cells were shown to have enhanced inflammatory transcriptomes and an impaired uptake of A β _{1–42}.

A recently completed GWAS coupled with longitudinal PET scans identified IL1RAP as a potential risk factor. IL1RAP is involved in the phenotypic switching of microglia. Individuals with the rs12053868-G SNP had a higher chance of progressing from MCI to AD as well as higher accumulation rates of A β , with further PET scans revealing lower rates of microglial-mediated inflammation (Ramanan *et al.*, 2015). These data highlight the intricate link between neuroinflammation and the immune system in AD. An extensive study, in which 85 133 independent samples from both control and LOAD individuals were examined, identified two novel rare coding variants in *PLCG2* and *ABI3*, in addition to a new variant in TREM2 (Sims *et al.*, 2017). *PLCG2* encodes the protein PLC γ 2, a phospholipase that hydrolyzes inositol 1,4,5-bisphosphate to generate inositol 1,4,5-trisphosphate and DAG. Interestingly, this variant is protective in AD, with an odds ratio of 0.68. *PLCG2* is primarily expressed in microglia,

with *PLCG2* variants leading to *PCLG2*-associated antibody deficiency and immune dysregulation disorders (Milner, 2015). *ABI3* is suggested to have a role in the innate immune response, in particular through IFN-mediated pathways (Sims *et al.*, 2017). *CRI* encodes the complement receptor 1, a protein involved in the regulation of the complement system in immunity. Critically, it is involved in the enhancement of phagocytosis of particles that have been opsonized (Fonseca *et al.*, 2016). There are currently four SNPs identified in *CRI* that confer increased AD risk (Zhu *et al.*, 2015). Critically, the aforementioned genes as well as a number of other genes identified need to be further explored to confirm an altered functional role in microglia.

Targeting microglia

A considered approach is needed when targeting microglia therapeutically. As the CNS is composed of heterogeneous microglial populations, of which a number are involved in homeostatic roles, broad eliminations of microglial function are inappropriate. Rather, a more appropriate therapeutic strategy is one that results in a net shift of populations to a more protective phenotype. Disease state is also critical in the therapeutic management of microglia. Heightened microglial activity may indeed be beneficial during early stages of disease, yet detrimental during later stages (Butovsky and Weiner, 2018). This is of critical note as clinical trials in AD are moving further towards prodromal stages of disease, aiming to prevent rather than cure disease. Furthermore, issues arise when selecting what specifically to target. Certainly, targeting the associated proteins of immune-related risk genes is a novel personalized medicine approach for those that possess these mutations. However, for the vast majority of individuals, this is not feasible. The precise biological mechanisms by which these genes alter AD risk remains unknown.

Currently, there are no approved selective therapeutics directed towards microglia. However, a number of clinical trials are underway that work through modulating microglia. **Receptor-interacting serine/threonine-protein kinase 1** (RIPK1), an enzyme downstream of TNF α signalling, has been shown to mediate microglial responses in AD (Ofengeim *et al.*, 2017). Denali Therapeutics purportedly has an RIPK1 inhibitor that has now entered phase 1 trials (Mullard, 2018). GliaCure has a small molecule that claims to promote microglial phagocytosis through binding of the microglial purinergic **P2Y₆** receptor. It is currently in phase 1 trials, its safety being examined in both healthy individuals and those with AD (GliaCure, 2014, 2015). **GM-CSF** has been shown to reduce amyloid burden and increase microglial numbers in AD mice (Boyd *et al.*, 2010). Sargramostim, a recombinant form of GM-CSF, is currently in phase 2 trials (University of Colorado & Foundation, 2011). CSP-1103, a small molecule that binds to the APP intracellular binding domain, has been shown to modulate microglial phenotype both *in vitro* and *in vivo* (Porrini *et al.*, 2015). It is currently in phase 3 trials. A number of major pharmaceutical companies are indeed working with microglia and have made significant efforts to increase internal microglial research (Mullard, 2018).

Other microglial-targeting therapeutics have however failed. Receptor for advanced glycation endproducts is involved in both microglial A β recognition and inflammation (Burstein *et al.*, 2018). A small molecule antagonist against this receptor recently failed in phase 3 trials after it failed to meet primary outcomes. Minocycline, an anti-inflammatory antibiotic which has classically been described as a putative microglial inhibitor, was shown to be ineffective at modifying the disease (Huntington Medical Research, 2012). Indeed, this historical classification of minocycline has been shown to be incorrect, with evidence demonstrating that it is indeed not a *bona fide* microglial inhibitor (Moller *et al.*, 2016). As AD is indeed a heterogeneous disease, reducing it to a single therapeutic target may indeed be an incorrect approach. Future treatment strategies will most likely be combinatorial, addressing multiple aetiologies. In addition, novel microglial targets have been identified. Homing peptides directed towards microglia that contained siRNA for IRF5 resulted in a decrease in neuropathic pain (Terashima *et al.*, 2018). Injection of microglial precursor cells transduced with TREM2 *ex vivo* in an EAE model of multiple sclerosis facilitated the clearance of cellular debris and ameliorated the disease (Takahashi *et al.*, 2007).

A shifting of the microglial phenotypes can also be achieved by modulating the overarching process of neuroinflammation through targeting the so called 'master regulators'. One such regulator is the type-I IFN, which has been recently but consistently reported to be involved in microglial function. Type-I IFNs have been shown to have the ability to act as master regulators of the peripheral immune response, with evidence also supporting this role within the CNS (Akira *et al.*, 2006). C57BL/6 mice lacking type-I IFN signalling exhibit an immunocompetent phenotype but importantly fail to produce a robust neuroinflammatory response in models of traumatic brain injury, Parkinson's disease and AD (Taylor *et al.*, 2014; Karve *et al.*, 2016; Main *et al.*, 2016). Microglial type-I IFN signalling has shown to be critical to microglial pathology (McDonough *et al.*, 2017). In a number of recent studies aiming to characterize microglial phenotypes, type-I IFN signalling has been shown to be crucial for specific populations (Hickman *et al.*, 2013; Keren-Shaul *et al.*, 2017; Mathys *et al.*, 2017). Blocking type-I IFN signalling in lupus prevents microglial-mediated synapse loss (Bialas *et al.*, 2017). The most attractive evidence comes from a meta-analysis of microglial transcripts from 69 individual disease states including AD. Critically, across all datasets, a co-regulated IFN gene set was observed (Friedman *et al.*, 2018).

Other 'master regulators' have also been identified. Removal or inhibition of inducible (i)NOS in APP_{SWE}/PS1_{ΔE9} mice shifts the microglial phenotype, which results in decreased levels of A β . Functionally, this was shown to rescue cognition as measured through the radial arm maze behavioural test (Kummer *et al.*, 2011). Deletion of TNF type 1 death receptor TNFR1, the endogenous receptor for TNF α , in APP23 mice leads to decreased levels of A β as well as decreased numbers of CD11b + microglia in the entorhinal cortex (He *et al.*, 2007). Hippocampal injections of an adeno-associated virus (AAV) expressing IL-1 β into APP_{SWE}/PS1_{ΔE9} mice leads to increased numbers of arginase-1-positive microglia, which are associated with the clearance of A β plaques (Cherry *et al.*, 2015). Reductions in microgliosis and improvements in

cognition have been reported following AAV delivery of IL-4 or IL-10 to hippocampal regions of APP_{SWE}/PS1_{ΔE9} mice (Kiyota *et al.*, 2010; Kiyota *et al.*, 2012). In APP transgenic mice expressing astrocytic TGF β , decreased A β levels in parallel with increases in overall microgliosis were reported (Wyss-Coray *et al.*, 2001). This emerging body of work demonstrates that, at least as a proof of principle, targeting microglia does in fact ameliorate AD pathology.

Discussion

Current therapies for AD are symptomatic and, for the most part, ineffective. This is exacerbated by the notion that we are indeed unaware of the underlying and causative disease mechanisms in AD. There is a clear need for therapeutics that are able to target downstream effects of hallmark pathologies and as such manage disease exacerbation and progression. One such downstream effect is neuroinflammation in which a chronic form is seen in AD. The neuroinflammatory process is complex and multifaceted, with a number of considerations required regarding its management and modulation. Critical, however, are the class of resident CNS immune cells, microglia. It is only recently that research has begun to understand and appreciate the multitude of roles they play within AD and how this contributes to the pathology. The emerging literature suggests that targeting these cells presents as a novel therapeutic area for the management of AD.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY Harding *et al.* (2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander *et al.*, 2017a,b,c,d).

Acknowledgement

This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia.

Author contributions

Z.M., J.M.T. and P.C. all contributed to the writing of this manuscript.

Conflict of interest

The authors declare no conflicts of interest.

References

Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA *et al.* (2017). iPSC-derived human microglia-like cells to study neurological diseases. *Neuron* 94: 278–293.e9.

- Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. *Cell* 124: 783–801.
- Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA *et al.* (2017a). The Concise Guide To PHARMACOLOGY 2017/18: G protein-coupled receptors. *Br J Pharmacol* 174: S17–S129.
- Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E *et al.* (2017b). THE Concise Guide to PHARMACOLOGY 2017/18: Catalytic receptors. *Br J Pharmacol* 174: S225–S271.
- Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E *et al.* (2017c). The Concise Guide To PHARMACOLOGY 2017/18: Enzymes. *Br J Pharmacol* 174: S272–S359.
- Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD *et al.* (2017d). The Concise Guide To PHARMACOLOGY 2017/18: Overview. *Br J Pharmacol* 174: S1–S16.
- Antonucci F, Turola E, Riganti L, Caleo M, Gabrielli M, Perrotta C *et al.* (2012). Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. *EMBO J* 31: 1231–1240.
- Bachstetter AD, Van Eldik LJ, Schmitt FA, Neltner JH, Ighodaro ET, Webster SJ *et al.* (2015). Disease-related microglia heterogeneity in the hippocampus of Alzheimer's disease, dementia with Lewy bodies, and hippocampal sclerosis of aging. *Acta Neuropathol Commun* 3: 32.
- Baker DJ, Petersen RC (2018). Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. *J Clin Invest* 128: 1208–1216.
- Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003). A cell surface receptor complex for fibrillar β -amyloid mediates microglial activation. *J Neurosci* 23: 2665–2674.
- Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT (2010). Regulation of tau pathology by the microglial fractalkine receptor. *Neuron* 68: 19–31.
- Bialas AR, Presumey J, Das A, van der Poel CE, Lapchak PH, Mesin L *et al.* (2017). Microglia-dependent synapse loss in type I interferon-mediated lupus. *Nature* 546: 539–543.
- Boche D, Perry VH, Nicoll JA (2013). Review: activation patterns of microglia and their identification in the human brain. *Neuropathol Appl Neurobiol* 39: 3–18.
- Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M *et al.* (2010). GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. *J Alzheimer's Dis: JAD* 21: 507–518.
- Brown GC, Neher JJ (2012). Eaten alive! Cell death by primary phagocytosis: 'phagoptosis'. *Trends Biochem Sci* 37: 325–332.
- Brown GC, Neher JJ (2014). Microglial phagocytosis of live neurons. *Nat Rev Neurosci* 15: 209–216.
- Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N *et al.* (2015). Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. *Immunity* 43: 92–106.
- Burstein A, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L (2018). Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease. *J Prev Alzheimers Dis* 5: 149–154.
- Butovsky O, Weiner HL (2018). Microglial signatures and their role in health and disease. *Nat Rev Neurosci* 19: 622–635.
- Calcoen D, Elias L, Yu X (2015). What does it take to produce a breakthrough drug? *Nat Rev Drug Discov* 14: 161–162.
- Cherry JD, Olschowka JA, O'Banion MK (2015). Arginase 1+ microglia reduce Abeta plaque deposition during IL-1beta-dependent neuroinflammation. *J Neuroinflammation* 12: 203.
- Conde JR, Streit WJ (2006). Microglia in the aging brain. *J Neuropathol Exp Neurol* 65: 199–203.
- Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G *et al.* (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261: 921–923.
- Crocker PR, McMillan SJ, Richards HE (2012). CD33-related siglecs as potential modulators of inflammatory responses. *Ann N Y Acad Sci* 1253: 102–111.
- Cronk JC, Filiano AJ, Louveau A, Marin I, Marsh R, Ji E *et al.* (2018). Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. *J Exp Med* 215: 1627–1647.
- Cummings JL, Morstorf T, Zhong K (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimer's Res Ther* 6: 37–37.
- D'Mello C, Le T, Swain MG (2009). Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. *J Neurosci* 29: 2089–2102.
- Deczkowska A, Matcovitch-Natan O, Tzitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A *et al.* (2017). Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN- γ -dependent manner. *Nat Commun* 8: 717.
- Dubois B, Albert ML (2004). Amnesic MCI or prodromal Alzheimer's disease? *Lancet Neurol* 3: 246–248.
- Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJM, Van Gool WA, Hoozemans JJM (2006). The significance of neuroinflammation in understanding Alzheimer's disease. *J Neural Transm* 113: 1685–1695.
- Floden AM, Combs CK (2011). Microglia demonstrate age-dependent interaction with amyloid-beta fibrils. *J Alzheimers Dis* 25: 279–293.
- Fonseca MI, Chu S, Pierce AL, Brubaker WD, Hauhart RE, Mastroeni D *et al.* (2016). Analysis of the putative role of CR1 in Alzheimer's disease: genetic association, expression and function. *PLoS One* 11: e0149792.
- Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA *et al.* (2018). Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. *Cell Rep* 22: 832–847.
- Fuger P, Hefendehl JK, Veeraraghavalu K, Wendeln AC, Schlosser C, Obermuller U *et al.* (2017). Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging. *Nat Neurosci* 20: 1371–1376.
- Garcia-Reitboeck P, Phillips A, Piers TM, Villegas-Llerena C, Butler M, Mallach A *et al.* (2018). Human induced pluripotent stem cell-derived microglia-like cells harboring TREM2 missense mutations show specific deficits in phagocytosis. *Cell Rep* 24: 2300–2311.
- Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S *et al.* (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330: 841–845.
- Ginhoux F, Lim S, Hoeffel G, Low D, Huber T (2013). Origin and differentiation of microglia. *Front Cell Neurosci* 7: 45.

- Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH *et al.* (2015). Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. *Nature* 518: 365–369.
- GliaCure I (2014). Safety, tolerability, and pharmacokinetic study of single ascending doses of GC021109 in healthy subjects.
- GliaCure I (2015). Study evaluating safety, tolerability, and PK of multiple ascending doses of GC021109 in subjects with mild to moderate Alzheimer's disease.
- Godbout J, Chen J, Abraham J, Richwine A, Berg B, Kelley K *et al.* (2005). Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. *FASEB J* 19: 1329–1331.
- Gomez-Nicola D, Franssen NL, Suzzi S, Perry VH (2013). Regulation of microglial proliferation during chronic neurodegeneration. *J Neurosci* 33: 2481–2493.
- Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K *et al.* (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* 78: 631–643.
- Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T *et al.* (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid- β . *Nat Immunol* 9: 857–865.
- Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S *et al.* (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucl Acids Res* 46: D1091–D1106.
- Hardy JA, Higgins GA (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science* 256: 184–185.
- Hargis KE, Blalock EM (2017). Transcriptional signatures of brain aging and Alzheimer's disease: what are our rodent models telling us? *Behav Brain Res* 322: 311–328.
- Hawkes N (2018). Pfizer abandons research into Alzheimer's and Parkinson's diseases. *BMJ* 360: k122.
- He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C *et al.* (2007). Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. *J Cell Biol* 178: 829–841.
- Heneka MT, Kummer MP, Latz E (2014). Innate immune activation in neurodegenerative disease. *Nat Rev Immunol* 14: 463–477.
- Henry CJ, Huang Y, Wynne AM, Godbout JP (2009). Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1 β and anti-inflammatory IL-10 cytokines. *Brain Behav Immun* 23: 309–317.
- Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK *et al.* (2013). The microglial sensome revealed by direct RNA sequencing. *Nat Neurosci* 16: 1896–1905.
- Hong S, Dissing-Olesen L, Stevens B (2016). New insights on the role of microglia in synaptic pruning in health and disease. *Curr Opin Neurobiol* 36: 128–134.
- Huntington Medical Research I (2012). Minocycline in patients with Alzheimer's disease.
- Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S (1998). Microglia-specific localisation of a novel calcium binding protein, Iba1. *Mol Brain Res* 57: 1–9.
- Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC *et al.* (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 7: 257–262.
- Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML *et al.* (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *J Exp Med* 212: 287–295.
- Joshi P, Turola E, Ruiz A, Bergami A, Libera DD, Benussi L *et al.* (2014). Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles. *Cell Death Differ* 21: 582–593.
- Karve IP, Zhang M, Habgood M, Frugier T, Brody KM, Sashindranath M *et al.* (2016). Ablation of type-1 IFN signaling in hematopoietic cells confers protection following traumatic brain injury. *eNeuro* 3: ENEURO.0128-0115.2016.
- Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK *et al.* (2017). A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* 169: 1276–1290 e1217.
- Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011). Physiology of microglia. *Physiol Rev* 91: 461–553.
- Kim J, Kwon J, Kim M, Do J, Lee D, Han H (2016). Low-dielectric-constant polyimide aerogel composite films with low water uptake. *Polymer J* 48: 829–834.
- Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T (2012). AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. *Gene Ther* 19: 724–733.
- Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T (2010). CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. *FASEB J* 24: 3093–3102.
- Kongsui R, Johnson SJ, Graham BA, Nilsson M, Walker FR (2015). A combined cumulative threshold spectra and digital reconstruction analysis reveal structural alterations of microglia within the prefrontal cortex following low-dose LPS administration. *Neuroscience* 310: 629–640.
- Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R *et al.* (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* 47: 566–581.e9.
- Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D *et al.* (2011). Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. *Neuron* 71: 833–844.
- Lawson LJ, Perry VH, Dri P, Gordon S (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. *Neuroscience* 39: 151–170.
- Lawson LJ, Perry VH, Gordon S (1992). Turnover of resident microglia in the normal adult mouse brain. *Neuroscience* 48: 405–415.
- Leavy O (2015). Neuroimmunology: TREM2 in Alzheimer disease. *Nat Rev Immunol* 15: 201–201.
- Lee CY, Landreth GE (2010). The role of microglia in amyloid clearance from the AD brain. *J Neural Transm (Vienna)* 117: 949–960.
- Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X *et al.* (2018). Elevated TREM2 gene dosage reprograms microglia responsiveness and ameliorates pathological phenotypes in Alzheimer's disease models. *Neuron* 97: 1032–1048 e1035.

- Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J *et al.* (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. *Neuron* 98: 1141–1154.e7.
- Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B *et al.* (2012). TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. *J Immunol* 188: 1098–1107.
- Lue LF, Schmitz C, Walker DG (2015). What happens to microglial TREM2 in Alzheimer's disease: immunoregulatory turned into immunopathogenic? *Neuroscience* 302: 138–150.
- Lund H, Pieber M, Parsa R, Grommisch D, Ewing E, Kular L *et al.* (2018). Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-beta signaling. *Nat Immunol* 19: 1–7.
- Maderna P, Godson C (2003). Phagocytosis of apoptotic cells and the resolution of inflammation. *Biochimica et Biophysica Acta (BBA) – Mol Basis Dis* 1639: 141–151.
- Main BS, Zhang M, Brody KM, Ayton S, Frugier T, Steer D *et al.* (2016). Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. *Glia* 64: 1590–1604.
- Mandrekar S, Jiang Q, Lee CYD, Koenigsnecht-Talboo J, Holtzman DM, Landreth GE (2009). Microglia mediate the clearance of soluble A β through fluid phase macropinocytosis. *J Neurosci* 29: 4252–4262.
- Mannix L (2018). What if we have got it wrong on Alzheimer's? In *The Age*.
- Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM *et al.* (2015). Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain* 138: 1738–1755.
- Martinez FO, Gordon S (2014). The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000prime Rep* 6: 13.
- Mathys H, Adaiக்கan C, Gao F, Young JZ, Manet E, Hemberg M *et al.* (2017). Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. *Cell Rep* 21: 366–380.
- McDonough A, Lee RV, Weinstein JR (2017). Microglial interferon signaling and white matter. *Neurochem Res* 42: 2625–2638.
- Milner JD (2015). PLAID: a syndrome of complex patterns of disease and unique phenotypes. *J Clin Immunol* 35: 527–530.
- Miyake K (2007). Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. *Semin Immunol* 19: 3–10.
- Moller T, Bard F, Bhattacharya A, Biber K, Campbell B, Dale E *et al.* (2016). Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor. *Glia* 64: 1788–1794.
- Morris GP, Clark IA, Vissel B (2014). Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. *Acta Neuropathol Commun* 2: 135.
- Mullard A (2018). Microglia-targeted candidates push the Alzheimer drug envelope. *Nat Rev Drug Discov* 17: 303–305.
- Neniskyte U, Neher JJ, Brown GC (2011). Neuronal death induced by nanomolar amyloid beta is mediated by primary phagocytosis of neurons by microglia. *J Biol Chem* 286: 39904–39913.
- Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ (2012). Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. *Neurobiol Aging* 33: e191–e112.
- Norden DM, Godbout JP (2013). Review: microglia of the aged brain: primed to be activated and resistant to regulation. *Neuropathol Appl Neurobiol* 39: 19–34.
- Ofengeim D, Mazzitelli S, Ito Y, DeWitt JP, Mifflin L, Zou C *et al.* (2017). RIPK1 mediates a disease-associated microglial response in Alzheimer's disease. *Proc Natl Acad Sci U S A* 114: E8788–E8797.
- Ohsawa K, Imai Y, Sasaki Y, Kohsaka S (2004). Microglia/macrophage-specific protein Iba1 binds to fimbria and enhances its actin-bundling activity. *J Neurochem* 88: 844–856.
- Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ *et al.* (2018). A transcriptomic atlas of aged human microglia. *Nat Commun* 9: 539.
- Orre M, Kamphuis W, Osborn LM, Jansen AHP, Kooijman L, Bossers K *et al.* (2014). Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. *Neurobiol Aging* 35: 2746–2760.
- Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P *et al.* (2011). Synaptic pruning by microglia is necessary for normal brain development. *Science* 333: 1456–1458.
- Perry VH, Nicoll JA, Holmes C (2010). Microglia in neurodegenerative disease. *Nat Rev Neurol* 6: 193–201.
- Pimplikar SW (2009). Reassessing the amyloid cascade hypothesis of Alzheimer's disease. *Int J Biochem Cell Biol* 41: 1261–1268.
- Plescher M, Seifert G, Hansen JN, Bedner P, Steinhauser C, Halle A (2018). Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model. *Glia* 66: 1464–1480.
- Pocock JM, Piers TM (2018). Modelling microglial function with induced pluripotent stem cells: an update. *Nat Rev Neurosci* 19: 445–452.
- Porrini V, Lanzillotta A, Branca C, Benarese M, Parrella E, Lorenzini L *et al.* (2015). CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. *Neuroscience* 302: 112–120.
- Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC *et al.* (2015). GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. *Brain* 138: 3076–3088.
- Ransohoff RM (2016). A polarizing question: do M1 and M2 microglia exist? *Nat Neurosci* 19: 987–991.
- Rawji KS, Mishra MK, Michaels NJ, Rivest S, Stys PK, Yong VW (2016). Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. *Brain* 139: 653–661.
- Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A [beta]-stimulated microglial activation. *J Neurosci* 29: 11982–11992.
- Sadallah S, Eken C, Schifferli JA (2011). Ectosomes as modulators of inflammation and immunity. *Clin Exp Immunol* 163: 26–32.
- Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009). Inflammation in Alzheimer's disease: amyloid- β oligomers trigger innate immunity defence via pattern recognition receptors. *Prog Neurobiol* 87: 181–194.
- Sarlus H, Heneka MT (2017). Microglia in Alzheimer's disease. *J Clin Invest* 127: 3240–3249.
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R *et al.* (2012). Microglia sculpt postnatal neural circuits in

- an activity and complement-dependent manner. *Neuron* 74: 691–705.
- Shastri A, Bonifati DM, Kishore U (2013). Innate immunity and neuroinflammation. *Mediators Inflamm* 2013: 1–19.
- Silvin A, Ginhoux F (2018). Microglia heterogeneity along a spatio-temporal axis: more questions than answers. *Glia* .
- Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J *et al.* (2017). Rare coding variants in *PLCG2*, *ABI3*, and *TREM2* implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet* 49: 1373–1384.
- Skaper SD, Facci L, Zusso M, Giusti P (2018). An inflammation-centric view of neurological disease: beyond the neuron. *Front Cell Neurosci* 12: 72.
- Streit WJ, Braak H, Xue QS, Bechmann I (2009). Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. *Acta Neuropathol* 118: 475–485.
- Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K (2006). Role of toll-like receptor signalling in Abeta uptake and clearance. *Brain* 129: 3006–3019.
- Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H (2007). *TREM2*-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. *PLoS Med* 4: e124.
- Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ (2014). Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. *Neurobiol Aging* 35: 1012–1023.
- Terashima T, Ogawa N, Nakae Y, Sato T, Katagi M, Okano J *et al.* (2018). Gene therapy for neuropathic pain through siRNA-IRF5 gene delivery with homing peptides to microglia. *Mol Ther Nucleic Acids* 11: 203–215.
- Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H *et al.* (2014). Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for *TREM2*. *Mol Neurodegener* 9: 20.
- University of Colorado D, & Foundation TD (2011). Study of the safety & efficacy of Leukine® in the treatment of Alzheimer's disease Available at <https://ClinicalTrials.gov/show/NCT01409915>.
- Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016). Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Curr Opin Neurobiol* 36: 74–81.
- Walker FR, Beynon SB, Jones KA, Zhao Z, Kongsui R, Cairns M *et al.* (2014). Dynamic structural remodelling of microglia in health and disease: a review of the models, the signals and the mechanisms. *Brain Behav Immun* 37: 1–14.
- Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML *et al.* (2015). *TREM2* lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* 160: 1061–1071.
- Weinhard L, di Bartolomei G, Bolasco G, Machado P, Schieber NL, Neniskyte U *et al.* (2018). Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction. *Nat Commun* 9: 1228.
- Wes PD, Sayed FA, Bard F, Gan L (2016). Targeting microglia for the treatment of Alzheimer's disease. *Glia* 64: 1710–1732.
- Wyss-Coray T, Lin C, Yan F, Yu G-Q, Rohde M, McConlogue L *et al.* (2001). *TGF-β1* promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. *Nat Med* 7: 612–618.
- Xanthos DN, Sandkuhler J (2014). Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. *Nat Rev Neurosci* 15: 43–53.
- Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT (2012). *PPARγ/RXRα*-induced and *CD36*-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. *J Neurosci* 32: 17321–17331.
- Zeisel A, Munoz-Manchado AB, Codeluppi S, Lonnerberg P, La Manno G, Jureus A *et al.* (2015). Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* 347: 1138–1142.
- Zhu XC, Yu JT, Jiang T, Wang P, Cao L, Tan L (2015). *CR1* in Alzheimer's disease. *Mol Neurobiol* 51: 753–765.